Hematology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Evaluate Daratumumab and Ibrutinib to Treat Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT)

   Jacksonville, Fla., Rochester, Minn.

   For cohort 1: The primary goal is to the determine the overall response rate after 6 cycles of treatment with daratumumab in combination with ibrutinib in patients who are on/or are previously treated with ibrutinib.
   For Cohort 2: The primary goal is to determine the overall response rate after 6 cycles of treatment with daratumumab in combination with ibrutinib in patients who are naive to ibrutinib treatment.
   
   Secondary Goals:
   For Cohort 1
   -Determine the best overall response rate to treatment with daratumumab plus ibrutinib at any time during the course of the therapy.
   -The overall incidence of MRD (minimal residual disease ) negative state and the time to achieving MRD negativity at any time during this therapy.
   -Progression free survival (as determined by the IWCLL criteria) among all patients.
   -The overall toxicity profile of daratumumab/ibrutinib treatment in this group of patients.
   
   For Cohort 2
   -Determine the best overall response rate to treatment with daratumumab plus ibrutinib at any time during the course of the therapy.
   -The overall incidence of MRD (minimal residual disease ) negative state and the time to achieving MRD negativity at any time during this therapy.
   -The overall toxicity profile of daratumumab/ibrutinib treatment in this group of patients.

2. A Study to Evaluate the Safety and Effectiveness of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this single-dose escalation study is to evaluate the safety and effectiveness of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma.

3. Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

   Rochester, Minn.

   This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

4. A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

   Jacksonville, Fla.

   The purpose of this study is to assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.

5. A Study of Proton Radiation Divided into Fewer Doses for Low Risk Prostate Cancer

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 treatments over 8½-9 weeks) with a higher daily dose of radiation (5 treatments over 1-2 weeks) to see if the effects of the treatments are similar or better.

6. Biorepository for Acute Leukemia Research

   Rochester, Minn.

   The purpose of this IRB protocol is to establish a specimen bank for research into acute leukemias. In particular, we plan to bank blood and bone marrow from patients with newly diagnoses or relapsed acute leukemia (AML or ALL) for future biological studies. By accruing samples both at initial diagnosis and at relapse, we will be able to investigate not only the biology of these marrow disorders, but also the changes that occur to render these disorders resistant to therapy. These activities are a first step toward identifying alternative therapies and subsequently beginning to personalize the therapy for these disorders.

7. Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

   Rochester, Minn.

   To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease (PTLD) after failing first line treatment.

8. A Study to Evaluate Reiki Therapy as an Intervention in Hematology/Oncology Cancer Patients Hospitalized in an Inpatient Setting

   Rochester, Minn.

   The primary purpose of this study is to evaluate the feasibility of offering and providing Reiki Therapy in hospitalized hematology/oncology cancer patients.

9. Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients With Suspected Lower Respiratory Tract Infection

   Rochester, Minn.

   This is a multicenter prospective collection of leftover respiratory tract secretions, paired blood and NP swabs, and clinical circumstances from pediatric HCT patients, followed by next generation genomic sequencing, transcriptome analysis, protein biomarker measurement, and statistical modeling.

10. IPSS Consortium Study

    Rochester, Minn.

    The overall objective of our network of investigators is to develop and conduct clinical trials and other large multi-centre studies in childhood stroke. Our specific aims are:

    Objective 1: To ascertain in a prospective, consecutive cohort study the numbers of newborns and children with ischemic stroke, their stroke sub-types and risk factors, their current treatments and outcomes within our centers. These data will provide the rationale and feasibility data for our group to design and implement the initial randomized controlled trials (RCTs) in paediatric stroke as well as other fundable grant proposals.

    Objective 2: To develop standardized data collection forms and an appropriate database with web-based data entry from multiple study sites.

    Objective 3: To develop standardized protocols for (1) diagnosis, (2) investigation of risk factors, (3) outcome assessment and 4) antithrombotic therapies of neonates and children with arterial ischemic stroke (AIS) and cerebral sinovenous thrombosis (CSVT)

    Objective 4: Obtain grant funding to support and conduct additional multi-centre IPSS sub-studies